ImmunoGen, Inc. Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 2, 2006

ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)


 
Massachusetts
0-17999
04-2726691
  
 
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
  


128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (617) 995-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

ITEM 8.01 - OTHER EVENTS

On October 4, 2006, ImmunoGen, Inc. (Nasdaq: IMGN) announced that sanofi-aventis has initiated clinical testing of AVE1642. AVE1642, a therapeutic antibody that binds to the Insulin-like Growth Factor 1 Receptor (IGF-1R), was developed by ImmunoGen and licensed to sanofi-aventis as part of a broader collaboration between the companies. IGF-1R is a receptor that is overexpressed on many different cancers. For each compound developed under this collaboration, ImmunoGen is entitled to receive milestone payments that could potentially total $21.5 to $30 million, plus royalties on sales. The initiation of clinical testing of AVE1642 triggers a $2 million milestone payment to ImmunoGen.


A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.



 
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.
  
Exhibit
99.1
  
Press Release of ImmunoGen, Inc. dated October 4, 2006
     






2
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
   
ImmunoGen, Inc.
  
   
(Registrant)
 
 
 
Date: October 4, 2006
  
/s/ Daniel M. Junius
  
 
 
 
   
Daniel M. Junius
   
Executive Vice President and Chief Financial Officer
     


3
 
EXHIBIT INDEX


Exhibit No.
  
Exhibit
99.1
  
Press Release of ImmunoGen, Inc. dated October 4, 2006
     

4